Publications by authors named "David R Strutton"

Claim this Profile
R
Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.
Derek Weycker, Raymond A Farkouh, David R Strutton, John Edelsberg, Kimberly M Shea

BMC Health Serv Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of pneumonia among children and adults with chronic medical conditions in Germany.
Stephen I Pelton, Kimberly M Shea, Raymond A Farkouh, David R Strutton, Sebastian Braun

BMC Infect Dis· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
Michele A Kohli, Raymond A Farkouh, Michael J Maschio, Lisa J McGarry, David R Strutton

Health Aff (Millwood)· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking risk for pneumococcal disease in adults: the role of risk stacking.
Stephen I Pelton, Kimberly M Shea, Derek Weycker, Raymond A Farkouh, David R Strutton

Open Forum Infect Dis· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine.
Stephen I Pelton, Derek Weycker, Raymond A Farkouh, David R Strutton, Kimberly M Shea

Clin Infect Dis· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rates of pneumococcal disease in adults with chronic medical conditions.
Kimberly M Shea, John Edelsberg, Derek Weycker, Raymond A Farkouh, David R Strutton

Open Forum Infect Dis· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor.
Rogier M Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A Farkouh, David R Strutton

Clin Ther· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.
Lisa J McGarry, Kristen E Gilmore, Jaime L Rubin, Keith P Klugman, David R Strutton

BMC Infect Dis· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Rogier M Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A Farkouh, David R Strutton

Clin Ther· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.
Raymond A Farkouh, Rogier M Klok, Maarten J Postma, Craig S Roberts, David R Strutton

Expert Rev Vaccines· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.
David R Strutton, Raymond A Farkouh, Jaime L Rubin, Lisa J McGarry, Paul M Loiacono

BMC Infect Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
David R Strutton, Raymond A Farkouh, Stephanie R Earnshaw, Sharon Hwang, Ulrike Theidel

J Infect· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.
Jaime L Rubin, Lisa J McGarry, David R Strutton, Keith P Klugman, Stephen I Pelton

Vaccine· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.
Jaime L Rubin, Lisa J McGarry, Keith P Klugman, David R Strutton, Kristen E Gilmore

BMC Infect Dis· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
G Thomas Ray, Stephen I Pelton, Keith P Klugman, David R Strutton, Matthew R Moore

Vaccine· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations.
Sonya J Snedecor, David R Strutton, Vincent Ciuryla, Elissa J Schwartz, Marc F Botteman

Vaccine· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Daniel J Isaacman, David R Strutton, Edward A Kalpas, Nathalie Horowicz-Mehler, Lee S Stern

Clin Ther· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia.
David R Strutton, Benjamin Gutierrez, Christopher M Blanchette

Am J Health Syst Pharm· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.
David R Strutton, Jonathan W Kowalski, Dee Anna Glaser, Paul E Stang

J Am Acad Dermatol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies.
David R Strutton, John G Walt

J Glaucoma· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making.
David R Strutton, Paul E Stang

J Pediatr· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of smoking on respiratory illness-related outpatient visits among 50- to 75-year-olds in the United States.
Lynn H Hoffman, David R Strutton, Paul E Stang, Susan L Hogue

Clin Ther· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis